I agree that this site is using cookies. You can find further informations here.
X
Pollyea, Daniel A.
90  results:
OpenAccess-fulltext X
Search for persons X
?
1

A Phase I/II Open-Label Study of Molibresib for the Treatme..:

Dawson, Mark A ; Borthakur, Gautam ; Huntly, Brian J.P...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932578/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
2

P536: A FIRST-IN-HUMAN PHASE 1 STUDY OF IO-202 (ANTI-LILRB4..:

Dinardo, Courtney ; Pollyea, Daniel ; Aribi, Ahmed...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428933/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
3

P525: LONG-TERM OUTCOMES OF STEM CELL TRANSPLANT IN OLDER P..:

Pratz, Keith ; Dinardo, Courtney ; L Arellano, Martha...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429562/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
4

Venetoclax response prediction in acute myeloid leukemia: a..:

Stevens, Brett ; Pollyea, Daniel A
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316264/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
5

Venetoclax plus azacitidine compared with intensive chemoth..:

Zeidan, Amer M ; Pollyea, Daniel A ; Borate, Uma...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285011/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
6

Targeting Acute Myeloid Leukemia Stem Cells Through Perturb..:

Sheth, Anagha Inguva ; Engel, Krysta ; Tolison, Hunter...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10592899/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
7

Top Advances of the Year in Leukemia: 2021:

Kent, Andrew ; Pollyea, Daniel A
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173446/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
8

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC ..:

Konopleva, Marina ; D. Dinardo, Courtney ; Sun, Yan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429507/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
9

Higher-dose venetoclax with measurable residual disease-gui..:

Gutman, Jonathan A ; Winters, Amanda ; Kent, Andrew...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542846/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
10

Treatment-free remission after ceasing venetoclax-based the..:

Chua, Chong Chyn ; Hammond, Danielle ; Kent, Andrew...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278306/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
11

Atezolizumab alone or in combination did not demonstrate a ..:

Gerds, Aaron T ; Scott, Bart L ; Greenberg, Peter...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864663/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
12

Outcomes in Patients with Poor-Risk Cytogenetics with or wi..:

Pollyea, Daniel A ; Pratz, Keith W ; Wei, Andrew H...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751752/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
13

Outcomes in Patients With Poor-risk Cytogenetics With or Wi..:

Pollyea, Daniel A ; Pratz, Keith W ; Wei, Andrew H...
qt14k765pj.  , 2022
Link: https://escholarship.org..
 
?
14

Identification and prioritization of myeloid malignancy ger..:

Yang, Fei ; Long, Nicola ; Anekpuritanang, Tauangtham...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9211447/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
15

Impact of Venetoclax and Azacitidine in Treatment-Naïve Pat..:

Pollyea, Daniel A ; DiNardo, Courtney D ; Arellano, Martha L...
info:eu-repo/semantics/altIdentifier/pmid/35046058.  , 2022
Link: http://hdl.handle.net/11..
 
1-15